SCHEMBL162703

SCHEMBL162703

CN1C(=O)NC(=O)C1(C)C

nearest known ligand 0.33

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ATAD2 Q6PL18 1/20 0.33
POLB P06746 1/20 0.32
AR P10275 2/20 0.32
AKR1B1 P15121 1/20 0.31
CRBN Q96SW2 1/20 0.31
PDK2 Q15119 1/20 0.30
PDK4 Q16654 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6579528 1.00 ATAD2 (0.33) ATAD2POLBARAKR1B1CRBN
SCHEMBL9775551 0.97 ATAD2 (0.32) ATAD2POLBARAKR1B1
SCHEMBL6235409 0.72
SCHEMBL8908315 0.72 POLB (0.34) ATAD2POLBAR
SCHEMBL23962148 0.72
SCHEMBL4621098 0.72
SCHEMBL542452 0.69 LMNA (0.36)
SCHEMBL1396164 0.69
SCHEMBL11250686 0.69 POLB (0.32) POLB
SCHEMBL11702613 0.69 POLB (0.31) POLBAR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 328 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111100587-A Graphene AB adhesive and preparation method thereof 苏州桐力光电股份有限公司 2020-05-05 CN claimed
CN-107841771-A It is a kind of based on the non-cyanide plating silvering solution composition of complexing ligands system and its application 厦门大学 2018-03-27 CN claimed
CN-105540749-B A kind of rural garbage is percolated liquid tower processing unit 徐州工程学院 2017-12-26 CN claimed
US-20020052511-A1 Process for the preparation of matrix metalloproteinase inhibitors BAILEY ANNE E (US) 2002-05-02 US claimed
US-20020019539-A1 Process for the preparation of matrix metalloproteinase inhibitors ABBOTT LABORATORIES 2002-02-14 US claimed
WO-2001074792-A2 PROCESS FOR THE PREPARATION OF MATRIX METALLOPROTEINASE INHIBITORS ABBOTT LABORATORIES (US) 2001-10-11 WO claimed
US-6235928-B1 ENZYME INHIBITOR MATRIX METALLOPROTEINASE FAMILY, INCLUDING COLLAGENASE, STROMELYSIN, AND GELATINASE, THE COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS PHARMACIA & UPJOHN COMPANY 2001-05-22 US claimed
EP-0571903-B1 A method for preparing low free formaldehyde methylol-hydantoins and compositions thereof LONZA AG (US) 1996-08-28 EP claimed
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-12354764-B2 Silver powder, method for producing same, and conductive resin composition MITSUI MINING & SMELTING CO., LTD. (JP) 2025-07-08 US disclosed
EP-4479138-A1 INHIBITORS OF RNA HELICASE DHX9 AND USES THEREOF Accent Therapeutics, Inc. (US) 2024-12-25 EP disclosed
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2024-09-12 US disclosed
WO-2024142789-A1 GOLD ELECTROPLATING SOLUTION AND METHOD FOR PRODUCING GOLD-ELECTROPLATED COATING 日本高純度化学株式会社 2024-07-04 WO disclosed
US-20230360820-A1 SILVER POWDER, METHOD FOR PRODUCING SAME, AND CONDUCTIVE RESIN COMPOSITION MITSUI MINING & SMELTING CO., LTD. (JP) 2023-11-09 US disclosed
EP-0144990-B1 PROCESS FOR PREPARING SILVER HALIDE EMULSION FUJI PHOTO FILM CO., LTD. (JP) 1990-04-25 EP disclosed
US-4665017-A GRAIN GROWTH PROMOTOR AND INHIBITOR FUJI PHOTO FILM CO., LTD. (JP) 1987-05-12 US disclosed
EP-0144990-A2 Process for preparing silver halide emulsion FUJI PHOTO FILM CO., LTD. (JP) 1985-06-19 EP disclosed
US-4436910-A SAPONIFICATION DEGUSSA AKTIENGESELLSCHAFT (DE) 1984-03-13 US disclosed
US-4282145-A Process for the preparation of azetidines GIST-BROCADES N.V. (NL) 1981-08-04 US disclosed
US-4073926-A BACTERICIDES, FUNGICIDES GLYCO CHEMICALS, INC. (US) 1978-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A ATAD2 1189/4885POLB 674/4885AR 851/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 ATAD2 471/4885POLB 350/4885AR 1597/4885
US-20020052511-A1 Process for the preparation of matrix metalloproteinase inhibitors MMP9, TIMP3, MMP2 ATAD2 3089/4885POLB 1444/4885AR 3986/4885
US-20020019539-A1 Process for the preparation of matrix metalloproteinase inhibitors MMP9, TIMP3, MMP2 ATAD2 3089/4885POLB 1444/4885AR 3986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.